Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Retained Earnings: 2022-2024

Historic Retained Earnings for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Dec 2024 value amounting to -$558.6 million.

  • NewAmsterdam Pharma Co N.V's Retained Earnings fell 47.40% to -$687.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$687.5 million, marking a year-over-year decrease of 47.40%. This contributed to the annual value of -$558.6 million for FY2024, which is 76.22% down from last year.
  • Latest data reveals that NewAmsterdam Pharma Co N.V reported Retained Earnings of -$558.6 million as of FY2024, which was down 76.22% from -$317.0 million recorded in FY2023.
  • NewAmsterdam Pharma Co N.V's Retained Earnings' 5-year high stood at -$140.0 million during FY2022, with a 5-year trough of -$558.6 million in FY2024.
  • Its 3-year average for Retained Earnings is -$338.5 million, with a median of -$317.0 million in 2023.
  • Data for NewAmsterdam Pharma Co N.V's Retained Earnings shows a maximum YoY slumped of 126.35% (in 2023) over the last 5 years.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's Retained Earnings (Yearly) stood at -$140.0 million in 2022, then plummeted by 126.35% to -$317.0 million in 2023, then crashed by 76.22% to -$558.6 million in 2024.